Fundamental Analysis of Mangalam Drugs and Organics Ltd
About the Company - Mangalam Drugs and Organics Ltd
Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 451.07 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2022.
Mangalam Drugs and Organics Ltd Profit & Loss Yearly Chart
Mangalam Drugs and Organics Ltd Growth
Compounded Sales Growth
10 Years:
12%
5 Years:
10%
3 Years:
-1%
TTM:
-1%
Compounded Profit Growth
10 Years:
%
5 Years:
-3%
3 Years:
%
TTM:
-813%
Stock Price CAGR
10 Years:
23%
5 Years:
26%
3 Years:
-17%
1 Year:
2%
Return on Equity
10 Years:
11%
5 Years:
7%
3 Years:
3%
Last Year:
-6%
Last Updated: July 24, 2024, 5:29 pm
Mangalam Drugs and Organics Ltd Balance Sheet
Last Updated: July 10, 2024, 7:32 pm
Month
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Sep 2023
Equity Capital
13
13
13
13
14
16
16
16
16
16
16
16
16
Reserves
25
13
10
16
39
70
88
80
88
115
135
136
123
Borrowings
61
73
77
78
60
66
69
65
52
70
88
89
89
Other Liabilities
23
16
25
63
47
38
54
50
75
64
90
119
159
Total Liabilities
122
115
125
170
160
190
227
211
231
264
328
360
387
Fixed Assets
57
55
53
53
54
93
102
103
101
118
135
142
151
CWIP
0
0
0
0
5
0
0
0
1
6
6
9
0
Investments
0
0
0
0
0
2
0
0
0
0
0
0
0
Other Assets
65
59
72
117
100
95
125
107
128
140
188
208
236
Total Assets
122
115
125
170
160
190
227
211
231
264
328
360
387
Mangalam Drugs and Organics Ltd Reserves and Borrowings Chart
Mangalam Drugs and Organics Ltd Cash Flow
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Cash from Operating Activity
-1
7
14
22
43
25
22
31
28
26
40
12
Cash from Investing Activity
-2
-2
-4
-11
-39
-16
-9
-7
-31
-27
-22
-18
Cash from Financing Activity
2
-5
-10
-11
-3
-9
-11
-23
3
3
-17
6
Net Cash Flow
-1
0
1
-0
0
-0
1
0
-1
1
1
-0
Mangalam Drugs and Organics Ltd Financial Efficiency Indicators
Month
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Debtor Days
21
70
88
73
37
45
61
28
52
52
38
46
Inventory Days
165
112
170
134
85
69
132
175
121
85
139
200
Days Payable
43
39
97
128
37
38
82
77
106
63
65
141
Cash Conversion Cycle
143
144
161
79
85
75
111
126
67
74
112
104
Working Capital Days
96
125
122
79
76
70
99
102
66
75
84
93
ROCE %
12%
-7%
6%
16%
30%
32%
25%
2%
11%
27%
18%
6%
Mangalam Drugs and Organics Ltd Financial Efficiency Indicators Chart
Mangalam Drugs and Organics Ltd Share Holding Pattern
Month
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Promoters
50.53%
50.53%
50.53%
50.53%
50.42%
50.41%
50.31%
50.31%
50.31%
50.31%
50.31%
50.31%
FIIs
0.00%
0.00%
0.00%
0.10%
0.10%
0.10%
0.10%
0.10%
0.10%
0.10%
0.10%
0.26%
DIIs
0.01%
0.01%
0.01%
0.01%
0.01%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
49.46%
49.46%
49.46%
49.36%
49.47%
49.49%
49.58%
49.59%
49.58%
49.59%
49.59%
49.42%
No. of Shareholders
21,827
21,071
20,668
20,084
18,988
18,483
17,911
17,943
17,890
17,978
18,610
19,173
Mangalam Drugs and Organics Ltd Shareholding Pattern Chart
No. of Mangalam Drugs and Organics Ltd Shareholders
This stock is not held by any mutual fund
Mangalam Drugs and Organics Ltd ROCE Trend
Mangalam Drugs and Organics Ltd EPS Trend
Mangalam Drugs and Organics Ltd Key Financial Ratios
Month
Mar 24
FaceValue
10.00
Basic EPS (Rs.)
-5.73
Diluted EPS (Rs.)
-5.73
Cash EPS (Rs.)
3.52
Book Value[Excl.RevalReserv]/Share (Rs.)
85.79
Book Value[Incl.RevalReserv]/Share (Rs.)
85.79
Revenue From Operations / Share (Rs.)
232.87
PBDIT / Share (Rs.)
11.05
PBIT / Share (Rs.)
1.80
PBT / Share (Rs.)
-7.00
Net Profit / Share (Rs.)
-5.73
NP After MI And SOA / Share (Rs.)
-5.73
PBDIT Margin (%)
4.74
PBIT Margin (%)
0.77
PBT Margin (%)
-3.00
Net Profit Margin (%)
-2.46
NP After MI And SOA Margin (%)
-2.46
Return on Networth / Equity (%)
-6.68
Return on Capital Employeed (%)
1.67
Return On Assets (%)
-2.72
Long Term Debt / Equity (X)
0.09
Total Debt / Equity (X)
0.64
Current Ratio (X)
1.07
Quick Ratio (X)
0.31
Interest Coverage Ratio (X)
1.26
Interest Coverage Ratio (Post Tax) (X)
0.34
Enterprise Value (Cr.)
233.69
EV / Net Operating Revenue (X)
0.63
EV / EBITDA (X)
13.36
MarketCap / Net Operating Revenue (X)
0.39
Price / BV (X)
1.08
Price / Net Operating Revenue (X)
0.39
EarningsYield
-0.06
Mangalam Drugs and Organics Ltd Profitability Ratios (%)
Mangalam Drugs and Organics Ltd Liquidity Ratios
Mangalam Drugs and Organics Ltd Liquidity Ratios (%)
Mangalam Drugs and Organics Ltd Interest Coverage Ratios (%)
Mangalam Drugs and Organics Ltd Valuation Ratios
Fair Value
Fair Value: 84.59
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
Overvalued: 23.10% compared to the current price 110
Default values used*: Deafault value of 15 for Stock P/E is used
Intrinsic Value: 48.01
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.
Overvalued: 56.36% compared to the current price 110
Default values used*: Deafault value of 15 for Stock P/E is used
Last 5 Year EPS CAGR: -43.25%
*Investments are subject to market risks
Strength and Weakness of Mangalam Drugs and Organics Ltd Stock
Strength
Weakness
The company has higher reserves (76.42 cr) compared to borrowings (73.75 cr), indicating strong financial stability.
The company has shown consistent growth in sales (270.77 cr) and profit (9.23 cr) over the years.
The stock has a low average ROCE of 14.83%, which may not be favorable.
The stock has a high average Working Capital Days of 90.58, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 106.75, which may not be favorable.
FAQ
What is the latest fair value of Mangalam Drugs and Organics Ltd?
The latest fair value of Mangalam Drugs and Organics Ltd is ₹84.59.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
The Market Cap of Mangalam Drugs and Organics Ltd is 174 Cr..
What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 27 July 2024?
The current stock price of Mangalam Drugs and Organics Ltd as on 27 July 2024 is 110.
What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2024?
In FY 2024, the High / Low of Mangalam Drugs and Organics Ltd stocks is 132/85.2.
What is the Stock P/E of Mangalam Drugs and Organics Ltd?
The Stock P/E of Mangalam Drugs and Organics Ltd is .
What is the Book Value of Mangalam Drugs and Organics Ltd?
The Book Value of Mangalam Drugs and Organics Ltd is 89.9.
What is the Dividend Yield of Mangalam Drugs and Organics Ltd?
The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.
What is the ROCE of Mangalam Drugs and Organics Ltd?
The ROCE of Mangalam Drugs and Organics Ltd is 1.19 %.
What is the ROE of Mangalam Drugs and Organics Ltd?
The ROE of Mangalam Drugs and Organics Ltd is 6.15 %.
What is the Face Value of Mangalam Drugs and Organics Ltd?
The Face Value of Mangalam Drugs and Organics Ltd is 10.0.
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mangalam Drugs and Organics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE